Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 8.90p
   
  • Change Today:
      0.000p
  • 52 Week High: 34.25
  • 52 Week Low: 8.77
  • Currency: UK Pounds
  • Shares Issued: 102.32m
  • Volume: 67,911
  • Market Cap: 9.11m
  • RiskGrade: 435

Valirx Overview

ValiRx accelerates the development of treatments in cancer and womens health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 2.7  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Valirx Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 n/a (3.55) (237.50)p n/a n/a n/a n/a 0.0%
31-Dec-18 n/a (4.83) (117.50)p n/a n/a n/a n/a 0.0%
31-Dec-19 n/a (2.72) (4,135.00)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (1.54) (3.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (1.68) (2.34)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Valirx Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-22 n/a (1.96) (2.67)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (2.02) (1.86)p n/a n/a n/a n/a 0.0%

Copyright © 2023 FactSet Research Systems Inc. All rights reserved.

Valirx Company Announcements

Incorporation of Inaphaea BioLabs Limited 01-Mar-2023 07:00 RNS
Second Price Monitoring Extn 24-Feb-2023 16:40 RNS
Price Monitoring Extension 24-Feb-2023 16:35 RNS

Latest Valirx Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Valirx Market Data

Currency UK Pounds
Share Price 8.90p
Change Today 0.000p
% Change 0.00 %
52 Week High 34.25
52 Week Low 8.77
Volume 67,911
Shares Issued 102.32m
Market Cap 9.11m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
38.36% below the market average38.36% below the market average38.36% below the market average38.36% below the market average38.36% below the market average
26.67% below the sector average26.67% below the sector average26.67% below the sector average26.67% below the sector average26.67% below the sector average
Price Trend
86.62% below the market average86.62% below the market average86.62% below the market average86.62% below the market average86.62% below the market average
55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Valirx Dividends

No dividends found

Trades for 23-Mar-2023

Time Volume / Share Price
15:57 23 @ 9.13p
13:53 28,603 @ 9.13p
13:51 30,000 @ 8.78p
11:20 911 @ 8.77p
10:18 3,250 @ 9.15p

Valirx Key Personnel

CFO Gerald Desler
CEO Suzanne Dilly

Top of Page